Regulation of vascular angiotensin II type 1 and type 2 receptor and angiotensin-(1–7)/MasR signaling in normal and hypertensive pregnancy

Clark, Caroline R.; Khalil, Raouf A.

doi:10.1016/j.bcp.2023.115963

Cited by 9 publications

(1 citation statement)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Angiotensin II receptor blockers have similar effects to angiotensin-converting enzyme inhibitors but with a different mechanism of action [ 43 , 44 ]. Their use during the second or third trimester of pregnancy can have a serious effect on the fetus, being associated with the impairment of fetal renal function which can cause a decrease in amniotic fluid volume, neonatal renal failure, anuria, fetal hypotension, and fetal or neonatal death [ 45 , 46 ]. A reported case in the literature is that of a 31-year-old woman with hypertension, treated with Irbesartan 2 × 150 mg/day, who presented to the gynecologist at 8 weeks after her last menstrual period, and Irbesartan treatment was immediately discontinued.…”

Section: Results Case Studies In Different Pharmacological Classesmentioning

confidence: 99%

Drugs Associated with Adverse Effects in Vulnerable Groups of Patients

Ștefan,

Nechita,

Dragostin

et al. 2024

Clinics and Practice

View full text Add to dashboard Cite

In recent years, a series of recommendations have been issued regarding the administration of drugs because of awareness of the serious side effects associated with certain classes of drugs, especially in vulnerable patients. Taking into account the obligation of the continuous improvement of professionals in the medical fields and the fact that we are in the midst of a “malpractice accusations pandemic”, through this work, we propose to carry out a “radiography” of the scientific literature regarding adverse effects that may occur as a result of the interaction of drugs with the physiopathological particularities of patients. The literature reports various cases regarding different classes of drugs administration associated with adverse effects in the elderly people, such as fluoroquinolones, which can cause torsade de pointes or tendinopathy, or diuretics, which can cause hypokalemia followed by torsade de pointes and cardiorespiratory arrest. Also, children are more prone to the development of adverse reactions due to their physiological particularities, while for pregnant women, some drugs can interfere with the normal development of the fetus, and for psychiatric patients, the use of neuroleptics can cause agranulocytosis. Considering the physiopathological particularities of each patient, the drug doses must be adjusted or even completely removed from the treatment scheme, thus requiring the mandatory active participation both of clinician pharmacists and specialists in the activity of medical-pharmaceutical analysis laboratories within the structure of hospitals.

show abstract

Section: Results Case Studies In Different Pharmacological Classesmentioning

confidence: 99%

Drugs Associated with Adverse Effects in Vulnerable Groups of Patients

Ștefan,

Nechita,

Dragostin

et al. 2024

Clinics and Practice

View full text Add to dashboard Cite

show abstract

Maternal Microvascular Dysfunction During and After Preeclamptic Pregnancy

Schwartz,

Stanhewicz

2024

Comprehensive Physiology

View full text Add to dashboard Cite

Preeclampsia, a pregnancy disorder characterized by de novo hypertension and maternal multisystem organ dysfunction, is the leading cause of maternal mortality worldwide and is associated with a fourfold greater risk of cardiovascular disease throughout the lifespan. Current understanding of the etiology of preeclampsia remains unclear, due in part to the varying phenotypical presentations of the disease, which has hindered the development of effective and mechanism‐specific treatment or prevention strategies both during and after the affected pregnancy. These maternal sequelae of preeclampsia are symptoms of systemic vascular dysfunction in the maternal nonreproductive microvascular beds that drives the development and progression of adverse cardiovascular outcomes during preeclampsia. Despite normalization of vascular disturbances after delivery, subclinical dysfunction persists in the nonreproductive microvascular beds, contributing to an increased lifetime risk of cardiovascular and metabolic diseases and all‐cause mortality. Given that women with a history of preeclampsia demonstrate vascular dysfunction despite an absence of traditional CVD risk factors, an understanding of the underlying mechanisms of microvascular dysfunction during and after preeclampsia is essential to identify potential therapeutic avenues to mitigate or reverse the development of overt disease. This article aims to provide a summary of the existing literature on the pathophysiology of maternal microvascular dysfunction during preeclampsia, the mechanisms underlying the residual dysfunction that remains after delivery, and current and potential treatments both during and after the affected pregnancy that may reduce microvascular dysfunction in these high‐risk women. © 2024 American Physiological Society. Compr Physiol 14:5703‐5727, 2024.

show abstract